Prostatic Artery Embolisation Versus Medical Treatment in Patients with Benign Prostatic Hyperplasia (PARTEM): A Randomised, Multicentre, Open-Label, Phase 3, Superiority Trial
Background: Prostatic artery embolisation (PAE) is a minimally invasive treatment of symptomatic benign prostatic hyperplasia (BPH). Our aim was to compare patient’s symptoms improvement after PAE and medical treatment. Methods: A randomised, open-label, superiority trial was set in 10 French hospitals. Patients with bothersome lower urinary tract symptoms (LUTS) related to BPH ≥50 ml resistant to alpha-blocker monotherapy were randomly assigned (1:1) to PAE or Combined Therapy ([CT], oral dutasteride 0·5 mg / tamsulosin hydrochloride 0·4 mg per day). Randomisation was stratified by centre, International Prostatic Symptom Score (IPSS) and prostate volume with a minimisation procedure to ensure balanced allocation. The primary outcome was the 9-month change in IPSS. Primary and safety analysis were done according to the intention-to-treat (ITT) principle among patients with an evaluable primary outcome (modified ITT). ClinicalTrials.gov Identifier: NCT02869971. Findings: Ninety patients were randomised from September 2016 to February 2020, and 44 and 43 patients assessed for primary endpoint in PAE and CT groups respectively. The 9-month change of IPSS was -10·0 (95% confidence interval [CI]: -11·8 to -8·3) and -5·7 (95% CI: -7·5 to -3·8) in the PAE and CT groups, respectively. This reduction was significantly greater in the PAE group than in the CT group (-4·4 [95% CI: -6·9 to -1·9], P=0·0008). The IIEF-15 score change was 8·2 (95% CI: 2·9 to 13·5) and -2·8 (95% CI: -8·4 to 2·8) in the PAE and CT groups, respectively. No treatment-related AE or hospitalisation was noticed. After 24 months, 5 and 18 patients had invasive prostate re-treatment in the PAE and CT group respectively. Interpretation: In patients with BPH ≥50 ml and bothersome LUTS resistant to alpha-blocker monotherapy, PAE provides more urinary and sexual symptoms score benefit than CT up to 24 months. Trial Registration Details: This study was registered with ClinicalTrials.gov Identifier: NCT02869971. Funding Information: The trial was sponsored by Assistance Publique - Hôpitaux de Paris and funded by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique) and supplemented with a research grant from Merit Medical. Declaration of Interests: NT, AD, CD, AR, GP, RCD, GR, FP, GK, VV, TM, HVK, ADLT, HK, RM, JFH, SD, JF, NBD, VKS, IDZ, HP, CD, and GC declare no conflict of interest. MS reports consulting fees from Merit medical. Ethics Approval Statement: The trial protocol was approved by an ethics committee (Comité de Protection des Personnes Ile de France VII). All participants provided written informed consent. conducted following the principles of the Declaration of Helsinki, Clinical Practice guidelines, and local guidelines.